Form 4: Alnylam Pharmaceuticals Director Michael Bonney Executes Option and Sells Shares Under 10b5-1 Plan

Director Michael Bonney exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael W. Bonney, a director of Alnylam Pharmaceuticals, executed a transaction involving the company's common stock on May 15, 2025.
• Bonney exercised stock options to acquire 11,250 shares at a price of $131.21 per share.
• Simultaneously, Bonney sold a total of 11,250 shares in multiple transactions at weighted average prices ranging from $267.14 to $284.22.
• These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 12, 2024.
• Following these transactions, Bonney directly owns 16,804 shares of Alnylam common stock and indirectly owns 4,000 shares through a trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, so they don't necessarily indicate a positive or negative outlook on the company's future. The fact that the director is selling shares could be seen as slightly negative, but the 10b5-1 plan mitigates this concern.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, suggesting they were planned well in advance and not based on any recent inside information.

Risks

• While the transactions are under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

Insider transactions are common, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. The market will likely assess the impact based on the size and frequency of such transactions.

Comparison to Industry Standards

• Comparing Bonney's transactions to other pharmaceutical company directors' dealings would require analyzing similar Form 4 filings.
• The use of a 10b5-1 plan is a common practice among corporate insiders to manage their stock holdings while mitigating legal risks, similar to practices seen at companies like Regeneron or Vertex.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on how the market interprets the insider selling, even under a 10b5-1 plan.

Key Dates

Keywords

Alnylam Pharmaceuticals, Michael Bonney, insider trading, Form 4, stock options, Rule 10b5-1, share sale